|
A.M. Mkrtumyan (1), S.V. Podachina (1), M.I. Sviridova (2)
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON CARDIOVASCULAR RISK MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№16 / 2016
|
|
M.B. Antsiferov (1), V.V. Fadeev (2), T.B. Morgunova (2)
MODERN APPROACHES TO THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№16 / 2016
|
|
M.B. Antsiferov (1), G. Schernthaner (2)
CURRENT APPROACHES TO THERAPY OF TYPE 2 DIABETES MELLITUS IN THE ERA OF NEW DATA ON CARDIOVASCULAR SAFETY
|
№16 / 2016
|
|
O.M. Koteshkova, L.P. Molina
EFFICIENCY OF MULTICOMPONENT THERAPY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (CLINICAL CASE)
|
№5 / 2016
|
|
E.V. Biryukova
EMPAGLIFLOZIN: ENHANCEMENT OF POTENTIALS OF THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2016
|
|
M.B. Antsiferov
APPLICATION OF SAXAGLIPTIN AND ITS COMBINATION WITH METFORMIN IN THE THERAPY OF TYPE 2 DIABETES MELLITUS IN ELDERLY PATIENTS
|
№5 / 2016
|
|
I.G. Bakulin, E.V. Vinnytskaya, Yu.G. Sandler, V.A. Keiyan, S.V.Rodionova
ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH DIABETES MELLITUS
|
№2 / 2016
|
|
N.A. Demidov (1), S.K. Zakharova (2), A.N. Zavyalov (3)
THE RESULTS OF MONITORING OF THE EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN INSULIN PREPARATIONS BIOSULIN R AND BIOSULIN N IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CLINICAL PRACTICE
|
№17 / 2015
|
|
A.F. Verbovoy, I.A. Tsanava, N.I. Verdovaya
ADIPOKINES AND HORMONAL AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND GOUT
|
№17 / 2015
|
|
M.B. Antsiferov (1), T.P. Nikitina (2), A.Yu. Rodionova (3), K.A. Kurbatova (2), T.I. Ionova (2)
HYPOGLYCEMIA AND QUALITY OF LIFE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№17 / 2015
|
|
G.R. Galstyan
HYPOGLYCEMIC EFFECTS OF FLOZINES COMPARED TO SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№17 / 2015
|
|
A.V. Pashentseva, A.F. Verbovoy
HYPOGLYCEMIC THERAPY AND CARDIOVASCULAR SAFETY
|
№13 / 2015
|
Русский
